What Noze does

Noze is a Montreal-based medical technology company developing an AI-powered digital olfaction platform for non-invasive, breath-based disease detection. The company's flagship product, the DiagNoze breathalyzer, combines nano-sensor arrays ("Smell on Silicon") derived from exclusively licensed NASA patents with a proprietary AI Perception Engine that translates volatile organic compound (VOC) patterns in exhaled breath into diagnostic outputs. The platform operates in two modes: SpotLight, which isolates a single known biomarker for rapid point-of-care triage, and DeepScan, which scans for disease-specific molecular fingerprints across multiple conditions.

The company's intended applications span five clinical verticals: oncology (breast and lung cancer detection), infectious diseases (tuberculosis and malaria screening in high-burden countries), metabolic health monitoring, critical care triage, and asthma/respiratory disease management. Clinical validation reported in peer-reviewed publications includes 85.4% accuracy for non-small cell lung cancer detection in a 158-patient study and 85-100% accuracy for breast cancer detection across stages in a 5,047-woman study. The Bill & Melinda Gates Foundation has provided $6.8 million in grants across three awards (March 2023, March 2024, July 2024) to support infectious disease applications, while the company has separately raised $24.4 million CAD from equity investors including TandemLaunch, Mistral Venture Partners, Fonds Innovexport, and Creative Destruction Labs.

Noze is a pre-revenue company: the DiagNoze device is under development, has not received FDA approval or clearance from any health authority, and is not commercially available. The company is pursuing FDA Breakthrough Device designation and targeting commercial launch by early 2026, with a Series B funding round targeting a $30 million USD minimum to support clinical trials. Revenue is expected to flow through hardware sales of the diagnostic device to healthcare providers, with initial geographic focus on high-burden countries for infectious disease screening via Gates Foundation-supported distribution. The company was founded in 2015 as Stratuscent, rebranded to Noze in 2023, and is led by CEO Karim Aly (MBA) and Founder/CTO Ashok Masilamani (PhD).

Name

Noze

Legal name

Noze Inc.

Website

https://noze.ca

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Noze is a Montreal-based medical technology company developing an AI-powered breathalyzer (DiagNoze) that uses nano-sensor arrays and proprietary neural models to detect diseases non-invasively across oncology, infectious disease, metabolic, and respiratory applications for healthcare providers globally.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)

akta.pro secondary industries

Odor Monitoring & Olfactometry (EUAHACAK), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Breath diagnostics
• Digital olfaction
• Medical breathalyzer
• Nano-sensor arrays
• Non-invasive diagnostics

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Diagnostic Devices: The company is developing breath-based diagnostic devices (DiagNoze) for clinical use. The device is currently under development and has not received FDA approval or any regulatory clearance. Revenue will be generated through device sales to healthcare providers once regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Noze develops an AI-powered digital olfaction platform that combines nano-sensor arrays (Smell on Silicon) with proprietary neural models (AI Perception Engine) to detect disease biomarkers in exhaled breath. The flagship DiagNoze® portable breathalyzer uses two operating modes — SpotLight™ for single-biomarker detection and DeepScan™ for multi-condition scanning — to support non-invasive screening for infectious diseases, cancer, metabolic, critical care, and respiratory conditions.

Product overview

Noze offers a unified breath-based diagnostic platform centered on the DiagNoze® device. The platform combines SpotLight™ (single biomarker rapid detection) and DeepScan™ (comprehensive disease fingerprint scanning) modes, powered by the proprietary AI Perception Engine and Smell on Silicon nano-sensor technology. Originally developed from NASA-licensed patents, the system analyzes volatile organic compounds in breath for disease detection across oncology, infectious diseases (tuberculosis, malaria), metabolic health, critical care, and respiratory conditions. The device is under development and not yet approved by FDA or any regulatory body.

Differentiator

Problem solved

Functional benefit

Brands

• DiagNoze: Medical breathalyzer device for tuberculosis detection and infectious disease screening
• SpotLight
• DeepScan

Products and services

• DiagNoze® A portable, handheld breath-based diagnostic device that uses nano-sensor arrays and proprietary AI to detect volatile organic compound biomarkers in exhaled breath for rapid, non-invasive screening of infectious diseases (e.g., tuberculosis, malaria), cancer signals, metabolic conditions, and respiratory conditions at the point of care. Targeted at hospitals, clinics, and point-of-care settings in both developed and high-burden countries.

Quantifiable outcome

• VOC biomarker panel detected non-small cell lung cancer with 85.4% accuracy in 2022 study of 158 patients
• +1 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Partnerships

One partnership is on record.

• Montreal Heart Institute (MHI)coreStrategic or Co-development Partner · 1 January 2021Partnership for 'Paradigm Shift in the Conduct of Clinical Trials' project. Noze is part of a consortium developing virtual clinical trial models combining innovative technologies. MHI received $9.35M from Quebec's Ministry of Economy and Innovation and $12.3M from private partners for this project.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Owlstone Medical: UK-based developer of the Breath Biopsy platform for non-invasive breath-based diagnostics across cancer, inflammatory and infectious disease. Most directly comparable competitor to Noze, addressing overlapping indications (lung cancer, infectious disease) with a similar VOC + AI approach.
• Hound Labs: US company developing ultra-sensitive breath analyzers for disease detection (and workplace cannabis testing). Comparable handheld breath-sensor product targeting point-of-care clinical diagnostics.
• Aerodiagnostics: Developer of exhaled breath analysis tools for inflammatory lung disease in pediatric and adult populations. Directly comparable breath-based diagnostic technology serving respiratory specialists.

Emerging players

• CMI Health (formerly Spirosure): Maker of FeNObreath exhaled nitric oxide devices for asthma and respiratory monitoring. Comparable handheld point-of-care breath diagnostics targeting clinicians in adjacent respiratory use cases.
• Beyond Air: Commercial-stage medical device company focused on inhaled nitric oxide for respiratory infections and lung conditions. Comparable portable respiratory diagnostic/therapeutic device company addressing pulmonary indications.

Broad incumbents

• Biodesix: US-based commercial lung diagnostics company with blood-based and proteomic tests for lung nodule management and infectious disease. Comparable in serving pulmonologists/oncologists with non-invasive diagnostic tests, though using blood rather than breath.
• Quanterix: Ultra-sensitive biomarker detection platform used in neurology, oncology, and infectious disease research and diagnostics. Comparable in pursuing biomarker-driven, AI-enabled disease detection, though based on blood-based Simoa technology rather than breath.
• Hologic: Large molecular diagnostics and women's health company with significant breast cancer screening franchise. Relevant incumbent in oncology diagnostics that Noze's breast-cancer breath test would compete with on workflow and cost.
• Abbott Diagnostics: Global diagnostics giant with point-of-care, immunoassay, and molecular testing platforms across infectious disease, metabolic, and oncology. Most likely strategic acquirer and competitor across multiple Noze target indications.
• Tempus AI: AI-driven precision medicine company combining multi-modal data (molecular, clinical, imaging) for oncology and other diseases. Comparable in using AI to translate complex molecular signals into diagnostic/therapeutic insight, though platform-centric rather than device-centric.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/noze_ai
• LinkedInlinkedin.com/company/noze-ai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noze